Mylan Institutional Drug Patent Portfolio
Mylan Institutional owns 1 orange book drug protected by 2 US patents Given below is the list of Mylan Institutional's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5866591 | Stable formulations of remifentanil | 10 Mar, 2018 | Expired |
| US5866591 | Stable formulations of remifentanil | 10 Sep, 2017 | Expired |
Mylan Institutional's Family Patents
Mylan Institutional Drug List
Given below is the complete list of Mylan Institutional's drugs and the patents protecting them.
1. Ultiva
Ultiva is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5866591
(Pediatric)
| Stable formulations of remifentanil |
10 Mar, 2018
(6 years ago)
| Expired |
| US5866591 | Stable formulations of remifentanil |
10 Sep, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ultiva's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List